|
rs1217691063
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate synthase promoter (TSER) polymorphisms in Indonesian children with and without leukemia.
|
17395259 |
2008 |
|
rs397507444
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The maternal methylenetetrahydrofolate reductase A1298C polymorphism was found to be an effect modifier of the maternal intron 4 polymorphism of the AKR1C3 gene (rs10508293) and the childhood leukemia risk.
|
18339682 |
2008 |
|
rs61754966
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Among these, an association with cancer was found most frequently for 657del5 (in leukemia/lymphoma and breast cancer) and I171V (in leukemia, breast, head and neck and colorectal cancers); however, other studies gave contradictory results.
|
18606567 |
2008 |
|
rs10508293
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The maternal methylenetetrahydrofolate reductase A1298C polymorphism was found to be an effect modifier of the maternal intron 4 polymorphism of the AKR1C3 gene (rs10508293) and the childhood leukemia risk.
|
18339682 |
2008 |
|
rs121913488
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The antileukemic activity of sorafenib was investigated in isogenic murine Ba/F3 AML cell lines that expressed mutant (ITD, D835G, and D835Y) or wild-type human FLT3, in primary human AML cells, and in a mouse leukemia xenograft model.
|
18230792 |
2008 |
|
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
KW-2449, a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase, is under investigation to treat leukemia patients.
|
19541823 |
2009 |
|
rs1217691063
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Recipient MTHFR polymorphisms (C677T) were associated with acute GvHD (P=0.03), and recipient VDR TaqI with TRM and overall survival (P=0.006 and P=0.04, respectively).Genetic factors that interfere with drug metabolisms are associated with treatment-related toxicities, GvHD and survival after HLA-identical HSCT in patients with leukemia and should be investigated prospectively.
|
19005482 |
2009 |
|
rs77375493
|
|
|
0.060 |
GeneticVariation |
BEFREE |
JAK2 (V617F)-positive ET may evolve in few instances into JAK2-negative leukemia.
|
19691103 |
2009 |
|
rs748843032
|
|
|
0.030 |
GeneticVariation |
BEFREE |
KW-2449, a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase, is under investigation to treat leukemia patients.
|
19541823 |
2009 |
|
rs1360131632
|
|
|
0.020 |
GeneticVariation |
BEFREE |
KW-2449, a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase, is under investigation to treat leukemia patients.
|
19541823 |
2009 |
|
rs749140677
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Recipient MTHFR polymorphisms (C677T) were associated with acute GvHD (P=0.03), and recipient VDR TaqI with TRM and overall survival (P=0.006 and P=0.04, respectively).Genetic factors that interfere with drug metabolisms are associated with treatment-related toxicities, GvHD and survival after HLA-identical HSCT in patients with leukemia and should be investigated prospectively.
|
19005482 |
2009 |
|
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although many imatinib-resistant mutations respond well to second-generation TKIs, the threonine-to-isoleucine mutation at codon 315 of the breakpoint cluster region/v-abl Abelson murine leukemia viral oncogene protein fusion Bcr-Abl (T315I) is insensitive to all currently available TKIs.
|
20564073 |
2010 |
|
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although strategies to overcome resistance-mediated T315I mutation may improve the survival of BCR-ABL-positive leukemia patients, there is little information on cell-based studies.
|
20471447 |
2010 |
|
rs121913507
|
|
|
0.040 |
GeneticVariation |
BEFREE |
In most patients with systemic mastocytosis (SM), including aggressive SM (ASM) and mast cell (MC) leukemia (MCL), neoplastic cells express the oncogenic KIT mutation D816V, which confers resistance to imatinib.
|
20553795 |
2010 |
|
rs121913682
|
|
|
0.040 |
GeneticVariation |
BEFREE |
In most patients with systemic mastocytosis (SM), including aggressive SM (ASM) and mast cell (MC) leukemia (MCL), neoplastic cells express the oncogenic KIT mutation D816V, which confers resistance to imatinib.
|
20553795 |
2010 |
|
rs121434592
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Recently, the E17K mutation in the AKT1 has been associated with multiple human malignancies and leukemia in mice.
|
20440266 |
2010 |
|
rs17433222
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Three SNPs (STAT6 rs703817, C1qG rs17433222, and MBP rs3794845) were significantly associated with childhood leukemia risk (p(trend) < 0.001, minP < 0.01).
|
20438785 |
2010 |
|
rs1801132
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The minor G allele of rs1801132 was protective in our cases (p = 1 × 10(-4)); for rs2228480, the heterozygous frequency was higher for cancer groups (p = 0.03); the SNP pairs rs2228480&rs3798577 and rs2234693&rs9340799 were in low LD; the haplotypes T-A of rs2234693&rs9340799 and G-C of rs2228480&rs3798577 showed a trend to be higher represented in breast cancers; T allele of rs2234693 was higher expressed in breast, colon cancers and leukemia; rs2077647 was associated with colon (p = 0.008, C-risk allele) and bladder (p = 0.01, T-risk allele) cancers.
|
20383761 |
2010 |
|
rs2075685
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We investigated some novel polymorphic variants of XRCC4, including C-1622T (rs7727691), G-1394T (rs6869366), G-652T (rs2075685), C-571T (rs2075686), intron3 DIP (rs28360071), S247A (rs3734091) and intron7 DIP (rs28360317), and analyzed the association of specific genotype with susceptibility to childhood leukemia.
|
20332465 |
2010 |
|
rs2075686
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We investigated some novel polymorphic variants of XRCC4, including C-1622T (rs7727691), G-1394T (rs6869366), G-652T (rs2075685), C-571T (rs2075686), intron3 DIP (rs28360071), S247A (rs3734091) and intron7 DIP (rs28360317), and analyzed the association of specific genotype with susceptibility to childhood leukemia.
|
20332465 |
2010 |
|
rs2077647
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The minor G allele of rs1801132 was protective in our cases (p = 1 × 10(-4)); for rs2228480, the heterozygous frequency was higher for cancer groups (p = 0.03); the SNP pairs rs2228480&rs3798577 and rs2234693&rs9340799 were in low LD; the haplotypes T-A of rs2234693&rs9340799 and G-C of rs2228480&rs3798577 showed a trend to be higher represented in breast cancers; T allele of rs2234693 was higher expressed in breast, colon cancers and leukemia; rs2077647 was associated with colon (p = 0.008, C-risk allele) and bladder (p = 0.01, T-risk allele) cancers.
|
20383761 |
2010 |
|
rs2228480
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The minor G allele of rs1801132 was protective in our cases (p = 1 × 10(-4)); for rs2228480, the heterozygous frequency was higher for cancer groups (p = 0.03); the SNP pairs rs2228480&rs3798577 and rs2234693&rs9340799 were in low LD; the haplotypes T-A of rs2234693&rs9340799 and G-C of rs2228480&rs3798577 showed a trend to be higher represented in breast cancers; T allele of rs2234693 was higher expressed in breast, colon cancers and leukemia; rs2077647 was associated with colon (p = 0.008, C-risk allele) and bladder (p = 0.01, T-risk allele) cancers.
|
20383761 |
2010 |
|
rs2234693
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The minor G allele of rs1801132 was protective in our cases (p = 1 × 10(-4)); for rs2228480, the heterozygous frequency was higher for cancer groups (p = 0.03); the SNP pairs rs2228480&rs3798577 and rs2234693&rs9340799 were in low LD; the haplotypes T-A of rs2234693&rs9340799 and G-C of rs2228480&rs3798577 showed a trend to be higher represented in breast cancers; T allele of rs2234693 was higher expressed in breast, colon cancers and leukemia; rs2077647 was associated with colon (p = 0.008, C-risk allele) and bladder (p = 0.01, T-risk allele) cancers.
|
20383761 |
2010 |
|
rs28360071
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We investigated some novel polymorphic variants of XRCC4, including C-1622T (rs7727691), G-1394T (rs6869366), G-652T (rs2075685), C-571T (rs2075686), intron3 DIP (rs28360071), S247A (rs3734091) and intron7 DIP (rs28360317), and analyzed the association of specific genotype with susceptibility to childhood leukemia.
|
20332465 |
2010 |
|
rs28360317
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We investigated some novel polymorphic variants of XRCC4, including C-1622T (rs7727691), G-1394T (rs6869366), G-652T (rs2075685), C-571T (rs2075686), intron3 DIP (rs28360071), S247A (rs3734091) and intron7 DIP (rs28360317), and analyzed the association of specific genotype with susceptibility to childhood leukemia.
|
20332465 |
2010 |